[en] Sarcoidosis is a systemic disorder of unknown aetiology characterised by
noncaseating granulomas leading principally to bilateral hilar lymphadenopathies,
pulmonary infiltration and skin and eye lesions. Sarcoidosis may involve other
organs, including peripheral lymph nodes, liver, spleen, nervous and
musculoskeletal systems, heart, ear, nose and kidney. Although the clinical
involvement of liver and heart is relatively uncommon, hepatic and cardiac
granulomas are present at autopsy in about 70 to 80% and 25 to 50%, respectively,
of patients with this disease. The diagnosis of sarcoidosis includes compatible
clinical and/or radiological presentations and histological evidence of
noninfectious and noncaseating epitheloid cell granulomas in the absence of other
identifiable agents responsible for such histological lesions. Disease course is
variable and usually characterised by frequent remissions, but it may become
progressive and chronic in a small percentage of patients. The optimal treatment
of sarcoidosis remains poorly defined. In patients with progressive pulmonary
dysfunction as well as in those with severe extrapulmonary localisations,
systemic corticosteroids usually represent the first approach, limited by long
term toxicity and frequent relapses after treatment interruption. In the presence
of refractory or corticosteroid-dependent forms of the disease, antimalarial
drugs or low dosage methotrexate may be used with prolonged benefit. The
indications for immunosuppressive agents such as azathioprine, chlorambucil,
cyclophosphamide and cyclosporin are uncommon and limited because of potentially
serious adverse effects and lack of information on their long term efficacy. In
the case of ocular and limited cutaneous manifestations, local corticosteroid
therapy may be useful.
Disciplines :
Rheumatology
Author, co-author :
Kaye, O.
Ribbens, Clio ; Université de Liège - ULiège > Rhumatologie
Kahn, M. F.
Malaise, Michel ; Université de Liège - ULiège > Département des sciences cliniques > Rhumatologie
Language :
English
Title :
Sarcoidosis: recognition and treatment guidelines
Publication date :
1997
Journal title :
BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Thomas PD, Hunninghake GW. Current concepts of the pathogenesis of sarcoidosis. Am Rev Respir Dis 1987; 135: 747-60
Tazi A, Soler P, Hance AJ. Pathogenesis of sarcoidosis. Rev Prat 1994; 44 (15): 2017-23
Fidler HM, Rook GA, Johnson N Mcl, et al. Mycobacterium tuberculosis DNA in tissue affected by sarcoidosis. BMJ 1993; 306: 546-9
Richter E, Greinert U, Kirsten D, et al. Assessment of mycobacterial DNA in cells and tissues of mycobacterial and sarcoid lesions. Am J Respir Crit Care Med 1996; 153: 375-80
Murdock J, Muller NL. Pulmonary sarcoidosis: changes on follow-up CT examination. Am J Roentgenol 1992; 159: 473-7
Winterbauer RH, Hutchinson JF. Clinical significance of pulmonary function tests: use of pulmonary function tests in management of sarcoidosis. Chest 1980; 78: 640-7
Sugie T, Hashimoto N, Iwai K. Clinical and autopsy studies on prognosis of sarcoidosis. Nippon Rinsho 1994; 52: 1567-70
Mitchell DN, Scadding JG, Heard BE, et al. Sarcoidosis: histological definition and clinical diagnosis. J Clin Pathol 1977; 30: 395-408
Gilman MJ, Wang KP. Transbronchial lung biopsy in sarcoidosis: an approach to determine the optimal numher of biopsies. Am Rev Respir Dis 1980; 122: 721-4
Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of the treatment of sarcoidosis. Am J Respir Crit Care Med 1994; 149: 893-8
Lawrence EC, Teague RB, Gottlieb MS, et al. Serial change in markers of disease activity with corticosteroid treatment in sarcoidosis. Am J Med 1983; 74: 747-56
DeRemee RA. The present status of therapy of pulmonary sarcoidosis: a house divided. Chest 1977; 71: 388-93
Jones E, Callen J. Hydroxychloroquine is effective therapy for control of cutaneous sarcoid granulomas. J Am Acad Dermatol 1990; 23: 487-9
Lacher MJ. Spontaneous remission or response to methotrexate in sarcoidosis. Ann Intern Med 1968; 60: 1247-8
Lower EE, Baughman RP. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci 1990; 229: 153-7
Veien NK, Brodthagen H. Cutaneous sarcoidosis treated with methotrexate. Br J Dermatol 1977; 97: 213-6
Soriano FG, Caramelli P, Nitrini R, et al. Neurosarcoidosis: therapeutic success with methotrexate. Postgrad Med J 1990; 66: 142-3
Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Int Med 1995; 155: 824-51
Kaye O, Palazzo E, Grossin M, et al. Low dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis. Br J Rheumatol 1995; 34: 642-4
Kataria YP. Chlorambucil in sarcoidosis. Chest 1980; 78: 36-42